SYK and non-Hodgkin lymphoma: Entospletinib, a more selective SYK inhibitor, has also shown notable activity in previously treated CLL, with good tolerance and is currently being evaluated in combination with obinutuzumab in CLL, SLL, and NHL (NCT 03010358)22,28.